三生制药与辉瑞达成60.5亿美元全球授权协议,辉瑞追加1.5亿美元获SSGJ-707中国内地独家商业化权利,并认购三生1亿美元股份,加快707项目全球开发商业化。
Source Link三生制药与辉瑞达成60.5亿美元全球授权协议,辉瑞追加1.5亿美元获SSGJ-707中国内地独家商业化权利,并认购三生1亿美元股份,加快707项目全球开发商业化。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.